Rhenman & Partners Asset Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,116	Closed	-$1.31M	–	91
2018 Q1	$1.31M	Hold	20,116	–	–	0.16%	71
2017 Q4	$1.47M	Buy	20,116 +9,005	+81%	+$745K	0.2%	76
2017 Q3	$1.02M	Buy	+11,111	New	+$852K	0.13%	79
2014 Q2	–	Sell	-2,178	Closed	-$557K	–	105
2014 Q1	$557K	Sell	2,178 -2,266	-51%	-$693K	0.17%	89
2013 Q4	$880K	Buy	+4,444	New	+$790K	0.34%	78

Other funds holding LUMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rhenman & Partners Asset Management's LUMO Position: Q2 2018 in Review

Rhenman & Partners Asset Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 20,116 shares — an estimated $1.31M sold.

Rhenman & Partners Asset Management first reported a position in LUMO in Q4 2013 and held it in 5 quarters. The position peaked at $1.47M in Q4 2017. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

Rhenman & Partners Asset Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Rhenman & Partners Asset Management sold 20,116 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $1.31M.
Rhenman & Partners Asset Management first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 5 quarters.
Rhenman & Partners Asset Management's Lumos Pharma, Inc. Common Stock position peaked at $1.47M in Q4 2017.
106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2018, filed 20 Jul 2018.